Tag Archives: Misfolded Proteins

The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)

Posted on December 15, 2017 by Dementia and Elderly Care News

Summary An experimental drug for the treatment of Huntington’s Disease shows early signs of being able to lower the level of misfolded proteins (safely) in the brains of patients, thereby having the potential to slow or halt the progression of … Continue reading →

Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest | Tagged Alzheimer's Disease, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Antisense Oligonucleotides (ASO), Biomedical Research Centres (NIHR), Canada, Clinical Trial NCT02519036, Gene Silencing to Suppress Transcription and Translation of Huntingtin, Gene-Silencing, Genetic Research, Genetics, Germany, Huntingtin Protein, Huntingtin Protein (HTT), Huntington Disease, Huntington's Disease (HD): an Autosomal-Dominant Inherited Neurodegenerative Disorder, Huntington's Disease Centre: UCL Institute of Neurology, Huntington’s Disease, Ionis Pharmaceuticals, IONIS-HTTRx: Huntingtin-Lowering Drug, α-Synuclein, α-Synuclein Aggregation, Leonard Wolfson Experimental Neurology Centre (LWENC), Leonard Wolfson Experimental Neurology Centre: University College London, Misfolded Proteins, Mutant HTT (mHTT) Protein, Mutant Huntingtin (mHTT), National Institute for Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuronal Loss, Neuroprotection, Prof. Giovanna Mallucci, Professor Sarah Tabrizi: IONIS-HTTRx Global Chief Investigator, Professor Sarah Tabrizi: UCL Institute of Neurology, Protein Misfolding, Roche, Synucleinopathy, Tau, Tau Protein, Tauopathy, University College London (UCL), University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust / University College London (NIHR) Biomedical Research Centre | Leave a comment

Structure of Tau Filaments in Alzheimer’s Disease Discovered (MRC / BBC News / Nature / NHS Choices)

Posted on July 6, 2017 by Dementia and Elderly Care News

Summary Research at the MRC Laboratory of Molecular Biology has taken advantage of a “resolution revolution” in microscopy to uncover the atomic structure of Tau filaments (one of the two types of the abnormal tangles associated with Alzheimer’s Disease). “Tau forms … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, National, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Abnormal Proteins, Abnormal Proteins (Alpha-Synuclein), Abnormal Proteins (Prions), Abnormal Proteins (Tau), Alzheimer’s Disease, Amyloid and Tau Imaging, Atomic Structure of Tau Filaments, BBC Health News, Behind the Headlines, Cryo-Electron Microscopy (Cryo-EM), Cryo-EM Structures of PHFs and SFs, Cryo-EM Structures of Tau Filaments, Department of Pathology and Laboratory Medicine: Indiana University School of Medicine, Drug Trials Failure Rate, European Union, Indiana University, Indiana University School of Medicine, Laboratory of Molecular Biology (LMB) Neuroscience Division, Medical Research Council (MRC), Misfolded Proteins, MRC Laboratory of Molecular Biology, MRC Laboratory of Molecular Biology (LMB), MRC Laboratory of Molecular Biology: Cambridge, MRC: Medical Research Council, Nature, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Research, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuropathologic Disorders, Neuropathology, Novel Targets in Neurodegeneration, Paired Helical Filaments (PHFs) and Straight Filaments (SFs), Protein Misfolding, Protofilament Interface in PHFs and SFs, Tau, Tau Aggregation, Tau Filaments, Tau Pathogenesis, Tau Pathology, Tau Protein, Tauopathy, Ultrastructural Polymorphs, United States, US National Institutes of Health, USA | Leave a comment

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Posted on April 20, 2017 by Dementia and Elderly Care News

Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →

Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans | Leave a comment

BBC iWonder Guide: How Close Are We to Stopping Alzheimer’s Disease? (BBC News)

Posted on November 27, 2016 by Dementia and Elderly Care News

Summary The BBC’s iWonder Guides provide “thought-provoking answers to the questions sparked by everyday life”. This particular collection of brief digestible articles, animations and videos covers: A frightening prospect (epidemiological statistics). How the disease affects your brain cells (an interactive … Continue reading →

Posted in Animal Studies, BBC News, In the News, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-Beta Clearance in Mice, Amyloid-Related Imaging Abnormalities (ARIA), Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E), Anti-Amyloid-β (Aβ) Immunotherapy Trials, BBC Health News, BBC iWonder Guide on Alzheimer's Disease, BBC iWonder Guides, Brain Drain: Brain Glymphatic Transport, Brain Glymphatic System, Clearance of Amyloid Beta Protein, CNS Lymphatic System: Hypothesis Regarding Poor Sleep Patterns and Neuropathology, Dementia Prevalence, Drug Side-Effects, Drug Trials, Glymphatic System, iWonder Guides (BBC), Lifestyle Risk Factors, Misfolded Proteins, Modifiable Risk Factors, Need For Sleep, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuronal Loss, Neuropathological Features, Neuropathology, Neuroprotective Lifestyles, Prevention, Prevention Agenda, Prevention Approaches, Prevention of Dementia, Preventive Health, Professor Maiken Nedergaard: University of Copenhagen, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Sleep Duration, Sleep Hygiene, Sleep Patterns, Sleeping Well, Tau Tangles, Therapeutic-Induced ARIA, Treatment Side-Effects: Therapeutic-Induced ARIA, University of Copenhagen | Leave a comment

Another Recent Alzheimer’s Disease Drug Trial Disappointment (Lancet)

Posted on November 24, 2016 by Dementia and Elderly Care News

Summary Researchers aimed to discover whether LMTM [Leuco-methylthioninium bis(hydromethanesulfonate] might be safe and effective for slowing disease progression in patients with mild to moderate Alzheimer’s Disease. LMTM had previously been found to work as a selective inhibitor of tau protein … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights | Tagged Aberdeen Biomedical Imaging Centre: University of Aberdeen, Abnormal Proteins (Tau), Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer's Disease Co-operative Study-Activities of Daily Living Inventory (ADCS-ADL) Scale, Alzheimer's Disease Research Unit, BioClinica (Lyon France), Canada, Clinicaltrials No. NCT01689246, CSD Biostatistics (USA), Department of Chemistry: University of Aberdeen, Department of Neurology: University of Southern California, Department of Neurosciences: University of California, Department of Psychiatry and Behavioral Sciences: University of Southern California, Douglas Mental Health University Institute (Montreal), Drug Trials, Drug Trials Failure Rate, European Union Clinical Trials Registry No. 2012-002866-11, France, Institute for Complex Systems and Mathematical Biology: University of Aberdeen, Keck School of Medicine: University of Southern California, Lancet, Leonard Davis School of Gerontology: University of Southern California, Leuco-Methylthioninium (LMTM), Leuco-Methylthioninium Bis(Hydromethanesulfonate): LMTM, McGill Centre for Studies in Aging, Medical Sciences and Nutrition: University of Aberdeen, Methaemoglobinaemia, Methylthioninium Chloride, Mild Alzheimer’s Disease, Misfolded Proteins, Moebius-Consult (Baar Switzerland), Nuffield Department of Clinical Neurosciences: University of Oxford, RadMD (USA), Reasons for Termination of Trials, Salamandra LLC (USA), School of Medicine: University of Aberdeen, School of Medicine: University of California, Switzerland, Tau, Tau Aggregation, Tau Aggregation Inhibitors, Tau Pathology, Tau Protein, Tau Tangles, Tau-Targeting Drugs, TauRx Therapeutics (Aberdeen), United States, University Hospitals and University of Geneva, University of Aberdeen, University of California, University of Oxford, University of Southern California, USA

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Posted on November 23, 2016 by Dementia and Elderly Care News

Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Alzheimer’s and Dementia (Journal), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Avid Radiopharmaceuticals (Philadelphia), BBC Health News, Big Pharma, Clearance of Amyloid Beta Protein, Drug Trials, Drug Trials Failure Rate, Eli Lilly, Eli Lilly and Company (Indianapolis), EXPEDITION Studies, Intervention Trials, β-amyloid, LZAM, LZAN, Mild Alzheimer’s Disease, Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, United States, USA | Leave a comment

Urine Test for Creutzfeldt-Jakob Disease (CJD)? (BBC News / MRC / JAMA Neurology / NEJM)

Posted on October 4, 2016 by Dementia and Elderly Care News

Summary It may one day be possible to use a non-invasive diagnostic urine test to discover whether or not patients have sporadic Creutzfeldt-Jakob Disease (sCJD). Full Text Link Reference A urine test for Creutzfeldt-Jakob Disease may be possible. London: Medical … Continue reading →

Tag Archives: Misfolded Proteins

The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)

Structure of Tau Filaments in Alzheimer’s Disease Discovered (MRC / BBC News / Nature / NHS Choices)

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Another Recent Alzheimer’s Disease Drug Trial Disappointment (Lancet)

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites